AVLN vs COAG
AVLN: Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases. COAG: Hemab Therapeutics is a clinical-stage biotechnology company developing innovative bispecific and monovalent antibody therapies for serious, rare blood coagulation disorders.
Side-by-side fundamentals
| Metric | AVLN | COAG | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $27.62 | $50.39 | |
| Market cap as of 2026-07-31 | $1.2B | $2.4B | |
| ROE as of 2026-07-31 | -63.8% | -34.8% | COAG higher |
| ROA as of 2026-07-31 | -57.2% | -32.8% | COAG higher |
| Debt / equity as of 2026-07-31 | 0.14 | 0.00 | COAG lower |
| Beta as of 2026-07-31 | -0.08 | -2.31 |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.